vs
CLOVER HEALTH INVESTMENTS, CORP.（CLOV）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是CLOVER HEALTH INVESTMENTS, CORP.的1.9倍（$906.4M vs $487.7M），Rollins, Inc.净利率更高（11.9% vs -10.1%，领先22.0%），CLOVER HEALTH INVESTMENTS, CORP.同比增速更快（44.7% vs 10.2%），Rollins, Inc.自由现金流更多（$111.2M vs $-69.0M），过去两年CLOVER HEALTH INVESTMENTS, CORP.的营收复合增速更高（18.6% vs 0.8%）
克利弗健康投资公司是2014年成立的美国医疗保健企业，主营联邦医疗保险优势计划保险产品，是与美国政府直接签约合作的机构。目前公司为美国11个州的联邦医疗保险参保人提供健康管理服务，并已于2021年1月8日公开上市。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
CLOV vs ROL — 直观对比
营收规模更大
ROL
是对方的1.9倍
$487.7M
营收增速更快
CLOV
高出34.5%
10.2%
净利率更高
ROL
高出22.0%
-10.1%
自由现金流更多
ROL
多$180.2M
$-69.0M
两年增速更快
CLOV
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $487.7M | $906.4M |
| 净利润 | $-49.3M | $107.8M |
| 毛利率 | — | — |
| 营业利润率 | -10.1% | 16.1% |
| 净利率 | -10.1% | 11.9% |
| 营收同比 | 44.7% | 10.2% |
| 净利润同比 | -123.2% | 2.5% |
| 每股收益（稀释后） | — | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLOVROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $487.7M | $912.9M | ||
| Q3 25 | $496.6M | $1.0B | ||
| Q2 25 | $477.6M | $999.5M | ||
| Q1 25 | $462.3M | $822.5M | ||
| Q4 24 | $337.0M | $832.2M | ||
| Q3 24 | $331.0M | $916.3M | ||
| Q2 24 | $356.3M | $891.9M |
净利润CLOVROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-49.3M | $116.4M | ||
| Q3 25 | $-24.4M | $163.5M | ||
| Q2 25 | $-10.6M | $141.5M | ||
| Q1 25 | $-1.3M | $105.2M | ||
| Q4 24 | $-22.1M | $105.7M | ||
| Q3 24 | $-9.2M | $136.9M | ||
| Q2 24 | $7.4M | $129.4M |
毛利率CLOVROL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 30.3% | — |
营业利润率CLOVROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | -10.1% | 17.5% | ||
| Q3 25 | -4.9% | 21.9% | ||
| Q2 25 | -2.2% | 19.8% | ||
| Q1 25 | -0.3% | 17.3% | ||
| Q4 24 | -6.4% | 18.1% | ||
| Q3 24 | -2.7% | 20.9% | ||
| Q2 24 | 2.0% | 20.4% |
净利率CLOVROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -10.1% | 12.8% | ||
| Q3 25 | -4.9% | 15.9% | ||
| Q2 25 | -2.2% | 14.2% | ||
| Q1 25 | -0.3% | 12.8% | ||
| Q4 24 | -6.6% | 12.7% | ||
| Q3 24 | -2.8% | 14.9% | ||
| Q2 24 | 2.1% | 14.5% |
每股收益（稀释后）CLOVROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | $0.34 | ||
| Q2 25 | — | $0.29 | ||
| Q1 25 | — | $0.22 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.3M | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $308.7M | $1.4B |
| 总资产 | $541.0M | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资CLOVROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $78.3M | $100.0M | ||
| Q3 25 | — | $127.4M | ||
| Q2 25 | — | $123.0M | ||
| Q1 25 | — | $201.2M | ||
| Q4 24 | $194.5M | $89.6M | ||
| Q3 24 | $288.0M | $95.3M | ||
| Q2 24 | $254.8M | $106.7M |
总债务CLOVROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CLOVROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $308.7M | $1.4B | ||
| Q3 25 | $340.9M | $1.5B | ||
| Q2 25 | $344.2M | $1.4B | ||
| Q1 25 | $336.1M | $1.4B | ||
| Q4 24 | $341.1M | $1.3B | ||
| Q3 24 | $342.2M | $1.3B | ||
| Q2 24 | $324.9M | $1.2B |
总资产CLOVROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $541.0M | $3.1B | ||
| Q3 25 | $559.7M | $3.2B | ||
| Q2 25 | $575.0M | $3.2B | ||
| Q1 25 | $583.7M | $2.9B | ||
| Q4 24 | $580.7M | $2.8B | ||
| Q3 24 | $653.0M | $2.8B | ||
| Q2 24 | $674.2M | $2.8B |
负债/权益比CLOVROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-66.9M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $-69.0M | $111.2M |
| 自由现金流率自由现金流/营收 | -14.1% | 12.3% |
| 资本支出强度资本支出/营收 | 0.4% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $-69.2M | $621.1M |
8季度趋势，按日历期对齐
经营现金流CLOVROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $-66.9M | $164.7M | ||
| Q3 25 | $12.1M | $191.3M | ||
| Q2 25 | $5.4M | $175.1M | ||
| Q1 25 | $-16.3M | $146.9M | ||
| Q4 24 | $34.8M | $188.2M | ||
| Q3 24 | $50.0M | $146.9M | ||
| Q2 24 | $44.8M | $145.1M |
自由现金流CLOVROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $-69.0M | $159.0M | ||
| Q3 25 | $11.4M | $182.8M | ||
| Q2 25 | $4.8M | $168.0M | ||
| Q1 25 | $-16.5M | $140.1M | ||
| Q4 24 | $33.3M | $184.0M | ||
| Q3 24 | $49.6M | $139.4M | ||
| Q2 24 | $44.4M | $136.4M |
自由现金流率CLOVROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | -14.1% | 17.4% | ||
| Q3 25 | 2.3% | 17.8% | ||
| Q2 25 | 1.0% | 16.8% | ||
| Q1 25 | -3.6% | 17.0% | ||
| Q4 24 | 9.9% | 22.1% | ||
| Q3 24 | 15.0% | 15.2% | ||
| Q2 24 | 12.5% | 15.3% |
资本支出强度CLOVROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 0.4% | 0.6% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.5% | 0.5% | ||
| Q3 24 | 0.1% | 0.8% | ||
| Q2 24 | 0.1% | 1.0% |
现金转化率CLOVROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | 6.04× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
